California
Biotech Insights
April 7, 2026
M&A, Deals, Partnerships: Aurinia Pharmaceuticals Acquires Kezar Life Sciences (SF) for ~$50M After Tang’s 2024 Bid Rejected Aurinia Pharmaceuticals (led by new CEO Kevin Tang as of last week) is acquiring South San Francisco-based Kezar Life Sciences for $6.95 cash per share (~$50 million total) plus a contingent value right (CVR) tied to future development […]
March 31, 2026
Recent Funding: Triangle Health (CA) Raises $4M for AI Health Assistant to Help Patients Navigate Medical Care Triangle Health raised $4 million led by SNR.vc to build an AI assistant that helps patients understand health conditions and explore treatment options by analyzing their complete medical history. The platform can brainstorm treatments, prepare doctor appointment questions, […]
March 24, 2026
Recent Funding: R1 Therapeutics (SF) Raises $77.5M Series A to Develop Once-Daily Pill for Kidney Disease Patients on Dialysis R1 Therapeutics launched with $77.5 million to develop AP306, a once-daily pill for hyperphosphatemia (high phosphate levels) in chronic kidney disease patients on dialysis. Unlike existing treatments that require patients to take 3-5 pills per meal […]
March 17, 2026
Recent Funding: Breakout Ventures Closes $114M Fund to Invest in Early-Stage Biotech California-based VC firm Breakout Ventures raised $114 million for its third fund to invest in approximately 20 early-stage biotech companies, writing first checks of $1 million to $5 million. The firm has already returned most of its first fund and a significant portion […]
March 10, 2026
Recent Funding: Tacit Therapeutics (SF) Raises $19M to Fix Genetic Diseases by Swapping Out Faulty RNA Tacit is developing a new approach called “trans-splicing” that replaces large broken sections of RNA with corrected versions, rather than editing DNA directly. Their first program targets Huntington’s disease, where they’ve successfully repaired 70% of faulty molecules in mouse […]
March 3, 2026
Recent Funding: BreezeBio (SF) Raises $60 Million to Advance mRNA Therapy for Type 1 Diabetes BreezeBio secured $60 million in Series B funding to move its lead program toward clinical trials, aiming to retrain the immune system in type 1 diabetes by delivering mRNA that teaches the body to stop attacking insulin-producing cells. The company’s […]
